Actavis’ Transformative Dealmaking
A steady stream of M&A and licensing activity, starting with the buyout of Andrx in 2006, spurred Actavis’ a.k.a. Watson’s transformation into a global specialty pharma. This led the way to the 2012 merger with Actavis and now the proposed buyout of Forest, creating a new, global specialty and generics player.
You may also be interested in...
The Nordic region’s vibrant life sciences ecosystem will be the chief focus for newly created Eir Ventures, a strategic partnership and investment company.
The International Coalition of Medicines Regulatory Authorities have sketched out the criteria that should be met before candidate coronavirus vaccines can proceed into late-stage trials, and agreed on how to design the studies and who should be included.
The UK’s Competition and Markets Authority has issued fines of nearly £2.3m after formally concluding that three firms participated in illegal arrangements over fludrocortisone that violated competition law.